Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States

Key Points Question To what extent are spatiotemporal trends in the COVID-19 pandemic in the United States associated with outcomes for patients with cancer infected with SARS-CoV-2? Findings This cohort study of 4749 patients with cancer and COVID-19 found no significant differences in outcomes across the 9 US census divisions. Overall, outcomes significantly improved between March and December 2020, and treatment at cancer centers in less densely populated counties was associated with better outcomes. Meaning These findings suggest that understanding the heterogeneity in COVID-19 outcomes between cancer centers could guide resource allocation and help the oncology community improve COVID-19 outcomes for this patient population.

[1]  J. Warner,et al.  Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium , 2021, Annals of Oncology.

[2]  Omar H. Butt,et al.  A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance , 2020, Cancer Cell.

[3]  J. Warner,et al.  Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study , 2020, Cancer discovery.

[4]  Jennifer L. Bell,et al.  Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial. , 2020, medRxiv.

[5]  L. Miller,et al.  Spatial Analysis of Global Variability in Covid-19 Burden , 2020, Risk management and healthcare policy.

[6]  Iván J Ramírez,et al.  COVID-19 Emergence and Social and Health Determinants in Colorado: A Rapid Spatial Analysis , 2020, International journal of environmental research and public health.

[7]  Alokkumar Jha,et al.  Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study , 2020, The Lancet.

[8]  E. Price-Haywood,et al.  Hospitalization and Mortality among Black Patients and White Patients with Covid-19 , 2020, The New England journal of medicine.

[9]  L. Dodd,et al.  Remdesivir for the Treatment of Covid-19 — Final Report , 2020, The New England journal of medicine.

[10]  J. Warner,et al.  The COVID-19 and Cancer Consortium: A Collaborative Effort to Understand the Effects of COVID-19 on Patients with Cancer , 2020, Cancer Cell.

[11]  Tisha M Felder,et al.  Racial and Geographic Disparities in Endocrine Therapy Adherence Among Younger Breast Cancer Survivors , 2020, American journal of clinical oncology.

[12]  M. Chua,et al.  SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China , 2020, JAMA oncology.

[13]  Huahao Shen,et al.  Risk of COVID-19 for patients with cancer , 2020, The Lancet Oncology.

[14]  S. Lipsitz,et al.  Geographic Distribution of Racial Differences in Prostate Cancer Mortality , 2020, JAMA network open.

[15]  Paul A. Harris,et al.  The REDCap consortium: Building an international community of software platform partners , 2019, J. Biomed. Informatics.

[16]  Gopal K Singh,et al.  Social Determinants of Health in the United States: Addressing Major Health Inequality Trends for the Nation, 1935-2016 , 2017, International journal of MCH and AIDS.

[17]  Avner Schlessinger,et al.  ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI , 2012 .

[18]  S. Pocock,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2007, Preventive medicine.

[19]  S. Pocock,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies , 2007, The Lancet.

[20]  Sharon-Lise T. Normand,et al.  Statistical and Clinical Aspects of Hospital Outcomes Profiling , 2007, 0710.4622.